Idexx Laboratories — Q1 2023 Earnings Presentation

4 slides from Idexx Laboratories's earnings presentation, May 2, 2023

Slide 1: IDEXX Q1 2023 Earnings Highlights
IDEXX Q1 2023 Earnings Highlights (NASDAQ: IDXX) Operating Diluted Revenue Profit Earnings Per Share $900M $280M $2.55 Reported growth: +8% 31.1% of Revenue Reported growth: +12% Organic growth: +10% YoY change in basis points: CAG Diagnostics Recurring Reported +150 bps Comparable growth: +18% Orga
Slide 2: 2023 Growth and Financial Performance Outlook
IDEXX Q1 2023 Earnings Highlights (NASDAQ: IDXX) 2023 Growth and Financial Performance Outlook Commentary • Updates revenue and EPS estimates, maintaining consistent high end goals for operating performance and incorporating positive revisions to low end of the outlook range to reflect solid Q1 perf
Slide 3: U.S. Companion Animal Practice Growth Update
U.S. Companion Animal Practice Growth Update As of March 31, 2023 Total Practice Revenue and Visit Growth Weighted Average Year-over-Year % Change Per Practice* 20% 17.4% 16.0% 15% 13.7% 12.2% 8.1% Practice Revenue 9.0% 10% 6.1% 5.5% 6.0% 10.8% 6.8% 5.8% 5.0% 5.3% 5.7% 4.7% 5.0% 4.7% 4.6% 4.3% 3.8%
Slide 4: Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice
U.S. Companion Animal Practice Growth Update As of March 31, 2023 Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice** 16% 12% + 9.0% + 9.5% Q1’2023 8% Year-Over-Year Growth (%) 4% 0.0% + 0.5% 0% 16% 12% 8% + 8.0% + 7.5% Q1’2022 4% - 1.0% + 0.5% 0% -4% 16% + 5.5% + 13.5% 12